Dr. Michael Merz is a clinical pharmacologist by training, with his main focus on drug safety questions during the past fourteen years. He led Quintiles’ Phase 1 clinic in Freiburg, Germany, and joined Novartis Pharma as Clinical Pharmacology Expert in 1998. At Novartis, he assumed responsibility as Head of Modeling and Simulation in Clinical Pharmacology, worked as Senior Medical Safety Expert in Clinical Safety and Epidemiology, and led the Systems Toxicology Section in Preclinical Safety. He has set up the company’s liver expert team in 2008 and has been leading the group since then. In addition, Dr. Merz is the project coordinator for the European Union’s IMI SAFE-T consortium, focusing on clinical qualification of liver, kidney, and vascular safety biomarkers.